-

GeneDx to Participate in Fall Investor Conferences

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences this fall:

  • UBS Genomic Medicine Summit – August 13-14, 2024
    Dana Point, California
    Future of Genetic Testing - Babies and Beyond Panel on Wednesday, August 14 at 8:00 a.m. PT
  • Morgan Stanley Healthcare Conference - September 4-6, 2024
    New York, New York
  • Wells Fargo Healthcare Conference - September 4-6, 2024
    Boston, Massachusetts
    Fireside chat on Thursday, September 5 at 8:45 a.m. ET
  • Jefferies London Healthcare Conference - November 19-21, 2024
    London, England

Live and archived webcasts of select presentations will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.

About GeneDx

At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It all starts with a single test. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.

Contacts

Investor Relations Contact:
investors@GeneDx.com

Media Contact:
press@GeneDx.com

GeneDx

NASDAQ:WGS

Release Summary
GeneDx (Nasdaq: WGS) today announced that company management will participate in upcoming investor conferences this fall.
Release Versions

Contacts

Investor Relations Contact:
investors@GeneDx.com

Media Contact:
press@GeneDx.com

More News From GeneDx

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GAITHERSBURG, Md.--(BUSINESS WIRE)--Announcing GeneDx's new genetic testing program with Zevra Therapeutics to support patients with suspected Niemann–Pick disease type C (NPC)....

GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced scientific contributions to be presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Meeting. GeneDx will present 18 accepted abstracts, including three platform presentations and two rapid fire poster talks, with research spanning sequencing innovations, breakthroughs in AI-supported interpretation...

GeneDx to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will participate in the upcoming TD Cowen and Barclays healthcare investor conferences....
Back to Newsroom